Skip to main content

Brady Kelly's Form 4 filing

Seres Therapeutics, Inc. (MCRB) · filed Aug 18, 2026

Accession no.
0001193125-26-355734
Filed
Aug 18, 2026, 5:33 PM ET
Trade date
Aug 15-17, 2026
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $291.2. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Brady KellyCIK 0002117686Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 15, 2026Common StockMOption exerciseAcquired+181–F1–8,743Direct
Aug 17, 2026Common StockSSaleDisposed−64$4.55−$291.28,679Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 15, 2026Common StockMOption exerciseDisposed−90$0.00$0179Direct
Aug 15, 2026Common StockMOption exerciseDisposed−91$0.00$0548Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Referenced by the price of 1 transaction in Table I.

Remarks

EVP, Chief Operating Officer

Read the full filing on SEC EDGAR (opens in a new tab)